Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Leflunomide-hydroxychloroquine combination for Sjögren’s shows potential

Publish date:: March 31, 2020

Key clinical point: Treatment with leflunomide and hydroxychloroquine is safe and may reduce disease activity in primary Sjögren’s syndrome.

Major finding: At 24 weeks, the mean difference in EULAR Sjögren’s syndrome disease activity index score in the leflunomide-hydroxychloroquine group, compared with the placebo group, was –4.35 points.

Study details: A placebo-controlled, double-blinded, phase 2a, randomized clinical trial in 29 patients with primary Sjögren’s syndrome.

Disclosures: The study was funded by ZonMw. The investigators reported no conflicts of interest.

Citation:

van der Heijden EHM et al. Lancet Rheumatol. 2020 Mar 26. doi: 10.1016/S2665-9913(20)30057-6.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Rheumatology

Osteoporosis prevalence in PsA similar to general population,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,